Clinical trials: Head Neck Cancer Squamous Cell Recurrent
Head and Neck Neoplasms
E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Recombinant human endostatin adenovirus injection is a novel anti-tumor gene therapy drug. E10A contains a recombinant human endostatin gene with the second-generation recombinant adenovirus as its vector.
- Trial name
- NCT02630264
- Testing
- Endostatins, Paclitaxel injection, Cisplatin injection
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Guangzhou Double Bioproducts Co., Ltd
Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Conventional biopsy and surgical tumor resection are invasive procedures that capture only one instance of the progression of the tumor. However, the genome of tumor is not static, but it is constantly altered during treatment.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
- Trial name
- NCT04490564
- Testing
- PD-L1 Kit
- Where
- 6 sites in Greece
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Pharmassist Ltd
Head and Neck Squamous Cell Carcinoma
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed…
- Trial name
- STELLAR-305 (NCT06082167)
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- 168 sites in United States, Argentina and 24 more
- Volunteers
- 600 people
- Sponsor
- Exelixis
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
Phase II Study of efficacy and safety of buparlisib (BKM120) plus paclitaxel versus placebo plus paclitaxel in recurrent or metastatic Head and Neck cancer previously pre-treated with a platinum therapy.The primary endpoint was…
- Trial name
- NCT01852292
- Testing
- Buparlisib, Paclitaxel
- Where
- 58 sites in United States, Australia and 16 more
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Squamous Cell Carcinoma
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT04843098
- Testing
- TL117, Paclitaxel
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Suzhou Junde Biotechnology Co., Ltd
Head and Neck Squamous Cell Carcinoma
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
This multi-center, open label phase II clinical study is performed in patients with recurrent metastatic squamous cell carcinoma of the head and neck progressed on prior anti-PD-1 mab ± platinum-based chemotherapy.
- Trial name
- NCT05044897
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 11 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent and/or Metastatic Head and Neck Cancer
Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head…
- Trial name
- SPECTRUM (NCT00460265)
- Testing
- ARM 2, ARM 1
- Volunteers
- 658 people
- Sponsor
- Amgen
Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective palliative treatment for head and neck cancer.
- Trial name
- NCT00003856
- Testing
- temoporfin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Quintiles, Inc.
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02143622
- Testing
- LJM716, cetuximab
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Squamous Cell Carcinoma of Head and Neck
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed…
- Trial name
- NCT04633278
- Testing
- CMP-001, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Neoplasms, Head and Neck
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic…
- Trial name
- NCT06062420
- Testing
- Dostarlimab, Belrestotug, Nelistotug
- Where
- 108 sites in United States, Argentina and 18 more
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2.
- Trial name
- DUAL-HN (NCT07617805)
- Testing
- EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor…
- Conditions
- Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07227168
- Testing
- STRO-004, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sutro Biopharma, Inc.
Head and Neck Squamous Cell Carcinoma
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04193293
- Testing
- Duvelisib, Pembrolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- SecuraBio
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Squamous Cell
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a…
- Trial name
- NCT00041626
- Testing
- INGN 201
- Where
- 8 sites in United States
- Sponsor
- Introgen Therapeutics
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell…
- Trial name
- NCT06525220
- Testing
- Petosemtamab, Pembrolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 699 people
- Sponsor
- Genmab
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics